Company Overview of Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc., a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company’s lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. Tamir Biotechnology also focuses on new drug application for unresectable malignant mesothelioma. In addition, it completed a Phase I clinical trial for the treatment of non-small cell lung cancer. The company was formerly known as Alfacell C...
12625 High Bluff Drive
San Diego, CA 92130
Founded in 1981
Key Executives for Tamir Biotechnology, Inc.
Chief Executive Officer, President, Secretary, and Director
Chief Financial Officer and Secretary
Chairman of the Thoracic Cancer Advisory Board
Special Advisor to Chief Executive Officer
Compensation as of Fiscal Year 2017.
Tamir Biotechnology, Inc. Key Developments
Tamir Biotechnology Announces Results from Pre-Clinical Investigational Study at Institute of Antiviral Research
Feb 22 16
Tamir Biotechnology announced results from a pre-clinical investigational study at the Institute of Antiviral Research at Utah State University. The study evaluated the anti-viral activity of ranpirnase in an established cell model of Zika virus infection. Overall, the study revealed that ranpirnase was active in blocking Zika virus relative to a control. In previous cell based studies, ranpirnase exhibited no cytotoxic effects at therapeutically effective dose levels. The clinical work with the Zika virus builds on years of work with other virally-caused pathologies such as Ebola. Results from a recent NIH-sponsored study on the Ebola virus gave 100% survival in ranpirnase-treated animals administered with therapeutic levels of the drug post-infection. The virus was undetectable in the serum of ranpirnase-treated mice at eight days post-infection. The company's clinical program is led by their phase II investigation of a topical formulation of ranpirnase in the treatment of HPV genital warts. This study is expected to begin enrollment in South America in February 2016. There are an estimated 14 million new and recurrent HPV infections per year in the US alone and the global HPV market is estimated to be over USD 2 billion in 2020. Ranpirnase for injection has been safely administered to over 1,000 subjects in previous oncology clinical trials.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries